
  
    
      
        Background_NNP
        Because_IN randomized_JJ cancer_NN screening_NN trials_NNS are_VBP very_RB
        expensive_JJ and_CC sometimes_RB difficult_JJ to_TO implement_VB ,_,
        observational_NN cancer_NN screening_NN studies_NNS can_MD play_VB an_DT
        important_JJ role_NN in_IN estimating_VBG the_DT efficacy_NN of_IN cancer_NN
        screening_NN during_IN early_JJ phases_NNS of_IN evaluation_NN of_IN the_DT
        screening_NN test_NN ._. However_RB the_DT standard_JJ methodology_NN for_IN
        observational_NN cancer_NN screening_NN studies_NNS has_VBZ various_JJ
        limitations_NNS ._. Case-control_NNP studies_NNS require_VBP adequate_JJ case_NN
        identification_NN ,_, eligibility_NN criteria_NNS for_IN equal_JJ access_NN of_IN
        cases_NNS and_CC controls_NNS to_TO screening_NN ,_, distinguishing_VBG symptomatic_JJ
        and_CC diagnostic_JJ tests_NNS ,_, and_CC adjustments_NNS for_IN self-selection_JJ
        bias_NN [_NN 1_CD ]_NN ._. Cohort_NNP studies_NNS often_RB involve_VBP natural_JJ history_NN
        models_NNS which_WDT rest_VBP upon_IN assumptions_NNS about_IN the_DT duration_NN of_IN
        preclinical_JJ cancer_NN or_CC the_DT growth_NN rate_NN of_IN the_DT tumor_NN ,_, the_DT
        sensitivity_NN of_IN the_DT screening_NN test_NN ,_, and_CC how_WRB screening_NN
        affects_VBZ cancer_NN mortality_NN ._. Some_DT examples_NNS can_MD be_VB found_VBN in_IN [_NN 2_CD
        3_CD 4_CD 5_CD 6_CD ]_NN ._. Importantly_NNP natural_JJ history_NN models_NNS based_VBN only_RB
        on_IN observational_NN data_NNS must_MD implicitly_RB assume_VB no_DT selection_NN
        bias_NN ,_, a_DT very_RB tenuous_JJ assumption_NN ._.
        In_IN contrast_NN ,_, periodic_JJ screening_NN evaluation_NN (_( PSE_NNP )_) ,_, which_WDT
        combines_VBZ estimates_NNS from_IN screened_VBD subjects_NNS to_TO estimate_VB the_DT
        reduction_NN in_IN population_NN cancer_NN mortality_NN associated_VBN with_IN
        periodic_JJ cancer_NN screening_NN [_NN 7_CD 8_CD 9_CD ]_NN ,_, does_VBZ not_RB involve_VB
        natural_JJ history_NN models_NNS and_CC the_DT associated_VBN assumptions_NNS ._.
        However_RB a_DT different_JJ set_NN of_IN assumptions_NNS is_VBZ required_VBN ._. In_IN
        certain_JJ situations_NNS these_DT assumptions_NNS may_MD be_VB more_RBR plausible_JJ
        than_IN the_DT natural_JJ history_NN assumptions_NNS ,_, so_RB in_IN some_DT
        circumstances_NNS ,_, the_DT method_NN may_MD be_VB complementary_JJ and_CC possibly_RB
        superior_JJ ,_, to_TO the_DT natural_JJ history_NN modeling_NN approach_NN ._.
        PSE_NNP starts_VBZ with_IN the_DT following_VBG estimates_NNS based_VBN directly_RB
        on_IN observed_VBD data_NNS from_IN a_DT few_JJ screenings_NNS at_IN regular_JJ intervals_NNS
        over_IN various_JJ ages_NNS (_( 1_LS )_) age-specific_JJ rates_NNS of_IN cancer_NN
        detection_NN on_IN first_JJ screening_NN ,_, interval_NN cancers_NNS ,_, and_CC cancer_NN
        detection_NN on_IN subsequent_JJ screenings_NNS ,_, and_CC (_( 2_LS )_) cancer_NN fatality_NN
        rates_NNS following_VBG cancer_NN detection_NN at_IN first_JJ screening_NN ,_,
        interval_NN cases_NNS ,_, and_CC cancer_NN detection_NN on_IN subsequent_JJ
        screening_NN ._. For_IN evaluation_NN it_PRP is_VBZ also_RB necessary_JJ to_TO estimate_VB
        (_( 1_LS )_) the_DT age-specific_JJ rate_NN of_IN cancer_NN detection_NN in_IN the_DT 
        absence_NN of_IN screening_NN and_CC (_( 2_LS )_) the_DT
        cancer_NN mortality_NN rate_NN following_VBG detection_NN in_IN the_DT 
        absence_NN of_IN screening_NN ._. Because_IN there_EX
        are_VBP no_DT randomized_JJ controls_VBZ the_DT challenge_NN is_VBZ to_TO estimate_VB
        rates_NNS in_IN the_DT absence_NN of_IN screening_NN in_IN a_DT manner_NN that_IN
        mitigates_NNS selection_NN bias_NN ._.
        In_IN estimating_VBG the_DT cancer_NN detection_NN rate_NN in_IN the_DT absence_NN
        of_IN screening_NN PSE_NNP mitigates_NNS selection_NN bias_NN in_IN a_DT unique_JJ
        manner_NN ._. As_IN will_MD be_VB discussed_VBN ,_, PSE_NNP estimates_VBZ the_DT
        age-specific_JJ detection_NN rate_NN in_IN the_DT absence_NN of_IN screening_NN as_IN
        the_DT sum_NN of_IN the_DT age-specific_JJ rates_NNS of_IN detection_NN for_IN cancers_NNS
        on_IN the_DT first_JJ screening_NN ,_, interval_NN cancers_NNS ,_, and_CC cancers_NNS on_IN
        subsequent_JJ screenings_NNS ,_, minus_CC the_DT age-specific_JJ rate_NN of_IN
        detection_NN for_IN cancer_NN on_IN the_DT first_JJ screening_NN in_IN subjects_NNS one_CD
        year_NN older_JJR ._. This_DT estimation_NN assumes_VBZ progressive_JJ detection_NN ,_,
        namely_RB that_IN once_RB a_DT cancer_NN is_VBZ detected_VBN on_IN screening_NN it_PRP will_MD
        always_RB be_VB detected_VBN on_IN screening_NN ._. Previous_JJ versions_NNS of_IN PSE_NNP
        made_VBD this_DT assumption_NN ._. However_RB progressive_JJ detection_NN is_VBZ not_RB
        likely_JJ to_TO hold_VB for_IN many_JJ types_NNS of_IN screening_NN modalities_NNS ._.
        Fortunately_RB ,_, as_IN we_PRP discuss_VBP ,_, if_IN progressive_JJ detection_NN is_VBZ
        violated_VBN ,_, the_DT estimated_VBN detection_NN rate_NN in_IN the_DT absence_NN of_IN
        screening_NN is_VBZ an_DT upper_JJ bound_VBN and_CC this_DT can_MD lead_VB to_TO useful_JJ
        estimates_NNS ._.
        In_IN estimating_VBG the_DT cancer_NN fatality_NN rate_NN following_VBG
        detection_NN in_IN the_DT absence_NN of_IN screening_NN ,_, earlier_JJR versions_NNS of_IN
        PSE_NNP used_VBD data_NNS from_IN refusers_NNS and_CC simply_RB assumed_VBD no_DT selection_NN
        bias_NN ._. To_TO avoid_VB this_DT assumption_NN (_( and_CC the_DT need_NN to_TO collect_VB
        data_NNS from_IN refusers_NNS )_) ,_, we_PRP estimated_VBD the_DT cancer_NN mortality_NN rate_NN
        following_VBG detection_NN in_IN the_DT absence_NN of_IN screening_NN by_IN the_DT
        cancer_NN mortality_NN rate_NN in_IN interval_NN cancers_NNS ._. As_IN we_PRP discuss_VBP ,_,
        this_DT also_RB leads_VBZ to_TO an_DT upper_JJ bound_VBN (_( i_NNP ._. e_SYM ._. optimistic_JJ )_)
        estimate_NN of_IN screening_NN efficacy_NN ._.
        Thus_RB ,_, this_DT version_NN of_IN PSE_NNP circumvents_VBZ the_DT problem_NN of_IN
        selection_NN bias_NN by_IN estimating_VBG an_DT upper_JJ bound_VBN ._. The_DT specific_JJ
        estimates_NNS of_IN cancer_NN detection_NN rates_NNS and_CC cancer_NN fatality_NN
        rates_NNS after_IN cancer_NN detection_NN are_VBP not_RB meaningful_JJ as_IN separate_JJ
        quantities_NNS ._. Fortunately_RB ,_, one_PRP can_MD longitudinally_RB combine_VB the_DT
        estimates_NNS to_TO estimate_VB an_DT upper_JJ bound_VBN on_IN the_DT reduction_NN in_IN
        population_NN cancer_NN mortality_NN associated_VBN with_IN periodic_JJ
        screening_NN ._. (_( Given_VBN these_DT data_NNS ,_, it_PRP is_VBZ not_RB possible_JJ to_TO
        estimate_VB reduction_NN in_IN population_NN cancer_NN mortality_NN for_IN other_JJ
        intervals_NNS between_IN screenings_NNS or_CC after_IN periodic_JJ screening_NN
        has_VBZ stopped_VBN )_) ._. The_DT longitudinal_NN combination_NN of_IN
        cross-sectional_JJ estimates_NNS ,_, which_WDT also_RB appears_VBZ in_IN earlier_JJR
        versions_NNS of_IN PSE_NNP [_NN 7_CD 8_CD 9_CD ]_NN ,_, is_VBZ similar_JJ to_TO G-_NNP computation_NN [_NN
        10_CD ]_NN and_CC the_DT method_NN of_IN Flanders_NNP and_CC Longini_NNP [_NN 11_CD ]_NN ._.
        If_IN an_DT upper_JJ bound_VBN estimate_NN of_IN screening_NN efficacy_NN is_VBZ
        small_JJ ,_, a_DT definitive_JJ randomized_JJ trial_NN to_TO evaluate_VB the_DT effect_NN
        of_IN screening_NN on_IN cancer_NN mortality_NN would_MD not_RB be_VB warranted_VBN ._.
        Thus_RB the_DT upper_JJ bound_VBN estimate_NN is_VBZ helpful_JJ only_RB if_IN is_VBZ not_RB
        unreasonably_RB large_JJ ._. To_TO determine_VB if_IN the_DT upper_JJ bound_VBN is_VBZ
        reasonable_JJ ,_, we_PRP estimated_VBD its_PRP$ value_NN using_VBG data_NNS from_IN screened_VBD
        subjects_NNS in_IN randomized_JJ trials_NNS of_IN colorectal_NN cancer_NN
        screening_NN [_NN 12_CD 13_CD ]_NN ,_, breast_NN cancer_NN screening_NN [_NN 14_CD ]_NN ,_, and_CC
        lung_NN cancer_NN screening_NN [_NN 15_CD 16_CD ]_NN ._. We_PRP then_RB compared_VBD this_DT
        estimate_NN to_TO a_DT modified_VBN PSE_NNP estimate_NN using_VBG data_NNS from_IN all_DT
        subjects_NNS ,_, so_IN that_IN estimates_NNS of_IN age-specific_JJ cancer_NN
        detection_NN in_IN the_DT absence_NN of_IN screening_NN and_CC cancer_NN mortality_NN
        in_IN the_DT absence_NN of_IN screening_NN are_VBP based_VBN on_IN data_NNS from_IN
        randomized_JJ controls_NNS and_CC refusers_NNS ._.
        We_PRP also_RB compared_VBD the_DT PSE_NNP estimates_NNS with_IN estimates_NNS based_VBN
        on_IN a_DT comparison_NN of_IN outcomes_NNS in_IN the_DT two_CD randomized_JJ groups_NNS ,_,
        adjusting_VBG for_IN refusers_NNS and_CC mitigating_VBG the_DT effect_NN of_IN
        dilution_NN after_IN stopping_VBG screening_NN [_NN 17_CD ]_NN ._. It_PRP is_VBZ important_JJ
        to_TO bear_VB in_IN mind_NN that_IN the_DT two_CD estimates_NNS are_VBP answering_VBG
        different_JJ questions_NNS ._. For_IN PSE_NNP ,_, the_DT question_NN is_VBZ "_'' What_WP is_VBZ the_DT
        effect_NN of_IN periodic_JJ screening_NN starting_VBG at_IN a_DT given_VBN age_NN and_CC
        ending_VBG at_IN a_DT later_JJ age_NN ?_. "_'' For_IN comparing_VBG randomized_JJ groups_NNS ,_,
        the_DT question_NN is_VBZ "_'' What_WP is_VBZ the_DT effect_NN of_IN the_DT particular_JJ
        screening_NN program_NN in_IN the_DT intervention_NN group_NN ?_. "_''
      
      
        Methods_NNP
        
          Simple_NN formulation_NN of_IN PSE_NNP
          We_PRP derive_VB a_DT simple_JJ formulation_NN of_IN PSE_NNP and_CC show_NN that_IN it_PRP
          gives_VBZ an_DT upper_JJ bound_VBN on_IN the_DT estimated_VBN reduction_NN in_IN
          population_NN cancer_NN mortality_NN ._.
          PSE_NNP requires_VBZ two_CD types_NNS of_IN data_NNS from_IN subjects_NNS who_WP
          receive_VBP two_CD or_CC more_JJR screenings_NNS at_IN regular_JJ intervals_NNS ._. The_DT
          first_JJ type_NN of_IN data_NNS are_VBP the_DT numbers_NNS of_IN subjects_NNS who_WP
          receive_VBP each_DT screen_NN and_CC who_WP are_VBP detected_VBN with_IN cancer_NN as_IN a_DT
          result_NN of_IN screening_NN or_CC in_IN the_DT interval_NN between_IN screens_NNS ._.
          (_( See_VB Tables_NNP 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_LS )_) The_DT second_JJ type_NN of_IN data_NNS are_VBP
          numbers_NNS of_IN subjects_NNS with_IN cancer_NN who_WP die_VBP from_IN cancer_NN and_CC
          are_VBP in_IN the_DT risk_NN set_VBD each_DT year_NN after_IN diagnosis_NN ._. (_( See_VB Table_NNP
          5_LS )_)
          PSE_NNP involves_VBZ three_CD steps_NNS :_: (_( 1_LS )_) estimate_NN the_DT
          age-specific_JJ incidence_NN of_IN cancer_NN associated_VBN with_IN
          different_JJ types_NNS of_IN detection_NN :_: first_JJ screen_NN ,_, interval_NN
          between_IN screens_NNS ,_, subsequent_JJ screen_NN ,_, refusers_NNS ,_, and_CC

          controls_NNS ,_, if_IN available_JJ ,_, (_( 2_LS )_) estimate_NN cancer_NN fatality_NN
          rates_NNS after_IN cancer_NN detection_NN ,_, and_CC (_( 3_LS )_) combine_VB these_DT
          estimates_NNS to_TO estimate_VB the_DT reduction_NN in_IN population_NN cancer_NN
          mortality_NN associated_VBN with_IN periodic_JJ cancer_NN screening_NN ._.
          Because_IN PSE_NNP requires_VBZ regular_JJ intervals_NNS ,_, the_DT analysis_NN
          is_VBZ restricted_VBN to_TO screenings_NNS that_WDT occur_VBP "_'' on-time_JJ "_'' ,_, namely_RB ,_,
          within_IN a_DT window_NN of_IN time_NN close_RB to_TO the_DT length_NN of_IN interval_NN ._.
          The_DT length_NN of_IN the_DT window_NN for_IN on-time_JJ screenings_NNS is_VBZ
          somewhat_RB arbitrary_JJ ._. A_DT very_RB wide_JJ window_NN discards_NNS
          relatively_RB few_JJ subjects_NNS ;_: however_RB it_PRP may_MD introduce_VB bias_NN
          into_IN calculations_NNS that_WDT are_VBP based_VBN on_IN assuming_VBG the_DT
          screening_NN interval_NN equals_VBZ the_DT midpoint_NN of_IN the_DT window_NN ._.
          Alternatively_RB ,_, a_DT narrow_JJ window_NN might_MD discard_VB too_RB much_JJ
          data_NNS ,_, increasing_VBG the_DT chance_NN for_IN bias_NN from_IN nonrandom_NN
          exclusion_NN of_IN subjects_NNS ._. In_IN designing_VBG a_DT study_NN for_IN PSE_NNP
          analysis_NN ,_, the_DT screening_NN intervals_NNS should_MD be_VB as_RB regular_JJ as_IN
          possible_JJ ._. Without_IN loss_NN of_IN generality_NN in_IN the_DT following_VBG
          discussion_NN ,_, we_PRP assume_VBP a_DT regular_JJ interval_NN between_IN screens_NNS
          of_IN 1_CD year_NN ._.
        
        
          Step_NN 1_CD :_: Age-specific_NNP cancer_NN incidence_NN
          PSE_NNP requires_VBZ estimates_NNS of_IN age-specific_JJ cancer_NN
          incidence_NN for_IN the_DT following_VBG types_NNS of_IN cancer_NN detection_NN :_:
          type_NN 
          F_NN ,_, detection_NN on_IN the_DT first_JJ
          screening_NN ;_: type_NN 
          I_PRP ,_, detection_NN in_IN the_DT interval_NN
          between_IN screenings_NNS ;_: type_NN 
          S_NNP ,_, detection_NN on_IN screening_NN
          subsequent_JJ to_TO the_DT first_JJ ;_: and_CC type_NN 
          A_DT ,_, detection_NN in_IN the_DT absence_NN of_IN
          screening_NN ._. The_DT incidence_NN of_IN type_NN 
          F_NN detection_NN at_IN age_NN 
          a_DT is_VBZ 
          q_NN 
          
            F_NN 
           (_( 
          a_DT )_) =_SYM 
          x_SYM 
          
            F_NN 
           (_( 
          a_DT )_) /_NN 
          n_NN 
          
            F_NN 
           (_( 
          a_DT )_) ,_, where_WRB 
          x_SYM 
          
            F_NN 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN of_IN subjects_NNS
          detected_VBD with_IN cancer_NN as_IN a_DT result_NN of_IN a_DT first_JJ screening_NN at_IN
          age_NN 
          a_DT and_NN 
          n_NN 
          
            F_NN 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN who_WP received_VBD the_DT
          first_JJ screening_NN at_IN age_NN 
          a_DT ._. The_DT incidence_NN of_IN type_NN 
          I_PRP detection_NN at_IN age_NN 
          a_DT is_VBZ 
          q_NN 
          
            I_PRP 
           (_( 
          a_DT )_) =_SYM 
          x_SYM 
          
            I_PRP 
           (_( 
          a_DT )_) /_NN 
          n_NN 
          
            I_PRP 
           (_( 
          a_DT )_) where_WRB 
          x_SYM 
          
            I_PRP 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN of_IN cases_NNS in_IN the_DT
          interval_NN after_IN screening_VBG at_IN age_NN 
          a_DT and_NN 
          n_NN 
          
            I_PRP 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN at_IN risk_NN at_IN the_DT
          start_NN of_IN the_DT interval_NN ._. The_DT incidence_NN of_IN type_NN 
          S_NNP detection_NN at_IN age_NN 
          a_DT is_VBZ 
          q_NN 
          
            S_NNP 
           (_( 
          a_DT )_) =_SYM 
          x_SYM 
          
            S_NNP 
           (_( 
          a_DT )_) /_NN 
          n_NN 
          
            S_NNP 
           (_( 
          a_DT )_) where_WRB 
          x_SYM 
          
            S_NNP 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN of_IN subjects_NNS
          detected_VBD with_IN cancer_NN as_IN a_DT result_NN of_IN an_DT "_'' on-time_JJ "_''
          screening_NN after_IN a_DT previous_JJ screening_NN at_IN age_NN 
          a_DT and_NN 
          n_NN 
          
            S_NNP 
           (_( 
          a_DT )_) is_VBZ the_DT number_NN of_IN subjects_NNS who_WP
          received_VBD an_DT "_'' on-time_JJ "_'' screening_NN after_IN the_DT previous_JJ
          screening_NN at_IN age_NN 
          a_DT ._. Although_IN a_DT type_NN 
          S_NNP detection_NN occurs_VBZ on_IN screening_NN at_IN
          age_NN 
          a_DT +_NN 1_CD ,_, for_IN mathematical_JJ
          convenience_NN ,_, it_PRP is_VBZ associated_VBN with_IN screening_NN at_IN age_NN 
          a_DT ._. We_PRP cannot_NN observe_VBP type_NN 
          A_DT detection_NN from_IN data_NNS on_IN subjects_NNS
          screened_VBD ._. However_RB ,_, as_IN derived_VBN in_IN [_NN 8_CD ]_NN ,_, one_PRP can_MD estimate_VB
          the_DT probability_NN of_IN type_NN 
          A_DT detection_NN by_IN
          
          q_NN 
          
            A_DT 
           (_( 
          a_DT )_) =_SYM 
          q_NN 
          
            F_NN 
           (_( 
          a_DT )_) +_NN 
          q_NN 
          
            I_PRP 
           (_( 
          a_DT )_) +_NN 
          q_NN 
          
            S_NNP 
           (_( 
          a_DT )_) -_: 
          q_NN 
          
            F_NN 
           (_( 
          a_DT +_NN 1_LS )_) ,_, (_( 1_LS )_)
          if_IN the_DT following_VBG key_JJ assumption_NN holds_VBZ ._.
          
            Assumption_NNP 1_CD ._. Progressive_NNP
            Detection_NNP 
          
          Once_RB a_DT subject_NN is_VBZ detectable_JJ on_IN screening_VBG the_DT subject_JJ
          will_MD always_RB be_VB detectable_JJ on_IN screening_NN ._.
          (_( The_DT quantity_NN 
          q_NN 
          
            F_NN 
           (_( 
          a_DT +_NN 1_LS )_) in_IN (_( 1_LS )_) is_VBZ the_DT cancer_NN
          detection_NN rate_NN on_IN the_DT first_JJ screening_NN among_IN subjects_NNS age_VBP 
          a_DT +_NN 1_CD at_IN first_JJ screening_NN ._. )_) The_DT
          graphical_JJ proof_NN of_IN (_( 1_LS )_) in_IN Figure_NN 1_CD generalizes_NNS the_DT
          graphical_JJ proof_NN in_IN [_NN 8_CD ]_NN to_TO allow_VB some_DT subjects_NNS with_IN
          preclinical_JJ cancer_NN to_TO be_VB missed_VBN on_IN screening_NN ._. In_IN Figure_NN
          1_CD ,_, 
          Assumption_NNP 1_CD corresponds_NNS to_TO δ_NN =_SYM 0_CD ,_,
          where_WRB δ_NN is_VBZ the_DT probability_NN that_IN some_DT individuals_NNS with_IN
          preclinical_JJ cancer_NN would_MD be_VB detected_VBN if_IN screened_VBD at_IN age_NN 
          a_DT but_CC missed_VBD if_IN screened_VBD at_IN age_NN 
          a_DT +_NN 1_CD ._. As_IN an_DT example_NN of_IN 
          Assumption_NNP 7_CD ,_, consider_VBP a_DT woman_NN who_WP
          would_MD have_VB been_VBN detected_VBN with_IN breast_NN cancer_NN at_IN age_NN 50_CD ,_,
          but_CC is_VBZ not_RB screened_VBD at_IN age_NN 50_CD for_IN reasons_NNS unrelated_JJ to_TO
          the_DT screening_NN or_CC any_DT possibility_NN of_IN cancer_NN ._. Under_IN 
          Assumption_NNP 1_CD ,_, if_IN the_DT woman_NN were_VBD
          screened_VBD at_IN age_NN 51_CD ,_, she_PRP would_MD be_VB detected_VBN with_IN cancer_NN ._.
          There_EX is_VBZ sometimes_RB confusion_NN about_IN how_WRB this_DT relates_VBZ to_TO
          sensitivity_NN of_IN the_DT screening_NN test_NN ._. As_IN shown_VBN in_IN Figure_NN 1_CD ,_, 
          Assumption_NNP 1_CD implies_VBZ that_IN the_DT
          sensitivity_NN of_IN the_DT screening_NN test_NN equals_VBZ 1_CD if_IN a_DT previous_JJ
          screening_NN test_NN would_MD have_VB detected_VBN cancer_NN ._.
          Ideally_RB 
          q_NN 
          
            F_NN 
           (_( 
          a_DT +_NN 1_LS )_) estimates_VBZ the_DT probability_NN of_IN
          detecting_VBG cancer_NN on_IN a_DT first_JJ screen_NN at_IN age_NN 
          a_DT +_NN 1_CD one_CD year_NN 
          after_IN the_DT start_NN of_IN the_DT study_NN ._.
          Because_IN there_EX are_VBP no_DT data_NNS on_IN subjects_NNS first_RB screened_VBD
          after_IN a_DT one_CD year_NN delay_NN ,_, we_PRP compute_VB 
          q_NN 
          
            F_NN 
           (_( 
          a_DT +_NN 1_LS )_) from_IN subjects_NNS age_VBP 
          a_DT +_NN 1_CD at_IN the_DT start_NN of_IN the_DT study_NN ._.
          This_DT procedure_NN requires_VBZ the_DT following_VBG additional_JJ
          assumption_NN ._.
          
            Assumption_NNP 2_CD ._. No_DT Birth_NNP Cohort_NNP
            Effect_NN 
          
          Given_VBN age_NN ,_, year_NN of_IN birth_NN provides_VBZ no_DT additional_JJ
          information_NN for_IN predicting_VBG cancer_NN incidence_NN on_IN the_DT first_JJ
          screen_NN ._.
        
        
          Step_NN 2_CD :_: Cancer-fatality_NNP rates_NNS among_IN cases_NNS
          PSE_NNP also_RB requires_VBZ estimates_NNS of_IN cancer_NN fatality-rates_JJ
          among_IN cases_NNS ._. The_DT estimated_VBN probability_NN of_IN death_NN from_IN
          cancer_NN within_IN 5_CD years_NNS of_IN type_NN 
          d_SYM cancer_NN detection_NN at_IN age_NN 
          a_DT is_VBZ
          
          pr_NN (_( cancer_NN death_NN |_NN type_NN 
          d_SYM detection_NN at_IN age_NN 
          a_DT )_)
          
          where_WRB 
          h_NN 
          
            di_FW 
           is_VBZ the_DT estimated_VBN case-fatality_JJ rate_NN from_IN cancer_NN in_IN
          year_NN 
          i_NNP after_IN type_NN 
          d_SYM detection_NN ,_, and_CC 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 
          i_NNP )_) is_VBZ the_DT probability_NN of_IN surviving_VBG
          competing_VBG risks_NNS from_IN age_NN 
          a_DT to_TO age_NN 
          a_DT +_NN 
          i_NNP ._. See_NNP also_RB Gooley_NNP et_CC al_NN [_NN 18_CD ]_NN ._.
          For_IN year_NN 
          j_NN after_IN type_NN 
          d_SYM detection_NN (_( 
          d_SYM =_SYM 
          F_NN ,_, I_PRP ,_, S_NNP )_) ,_, the_DT estimated_VBN
          case-fatality_JJ rate_NN from_IN the_DT cancer_NN under_IN study_NN is_VBZ 
          h_NN 
          
            dj_NN 
           =_SYM 
          x_SYM 
          
            dj_NN 
           /_NN 
          r_LS 
          
            dj_NN 
           ,_, where_WRB 
          x_SYM 
          
            dj_NN 
           is_VBZ the_DT number_NN of_IN cancer_NN deaths_NNS among_IN cases_NNS at_IN year_NN 
          j_NN after_IN type_NN 
          d_SYM detection_NN ,_, and_CC 
          r_LS 
          
            dj_NN 
           the_DT number_NN of_IN cases_NNS with_IN type_NN 
          d_SYM detection_NN who_WP are_VBP at_IN risk_NN at_IN year_NN
          
          j_NN since_IN detection_NN ._.
          We_PRP approximate_JJ 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 
          i_NNP )_) by_IN the_DT probability_NN of_IN surviving_VBG
          from_IN age_NN 
          a_DT to_TO age_NN 
          a_DT +_NN 
          i_NNP obtained_VBD from_IN demographic_JJ data_NNS
          stratified_JJ by_IN sex_NN [_NN 19_CD ]_NN ._. We_PRP approximate_JJ the_DT probability_NN
          of_IN surviving_VBG competing_VBG risks_NNS each_DT year_NN over_IN five_CD years_NNS as_IN
          the_DT probability_NN of_IN surviving_VBG competing_VBG risks_NNS at_IN the_DT
          midpoint_NN of_IN two_CD years_NNS ,_, i_NNP ._. e_SYM ._. ,_, 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 
          i_NNP )_) =_SYM 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 3_LS )_) for_IN 
          i_NNP =_SYM 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ._. This_DT lets_VBZ us_PRP
          approximate_JJ (_( 2_LS )_) by_IN
          
          pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN 
          d_SYM detection_NN at_IN age_NN 
          i_NNP )_) =_SYM 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 3_LS )_) 
          m_NN 
          
            d_SYM 
           ,_, (_( 3_LS )_)
          where_WRB is_VBZ the_DT estimated_VBN probability_NN of_IN cancer_NN death_NN
          within_IN five_CD years_NNS of_IN type_NN 
          d_SYM detection_NN conditional_JJ on_IN no_DT death_NN
          from_IN competing_VBG risk_NN and_CC 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 3_LS )_) is_VBZ the_DT approximate_JJ
          probability_NN of_IN surviving_VBG competing_VBG risks_NNS within_IN five_CD
          years_NNS of_IN type_NN 
          d_SYM detection_NN ._.
          A_DT major_JJ challenge_NN is_VBZ how_WRB to_TO estimate_VB 
          m_NN 
          
            A_DT 
           ,_, the_DT probability_NN of_IN cancer_NN fatality_NN within_IN five_CD
          years_NNS of_IN type_NN 
          A_DT detection_NN (_( i_NNP ._. e_SYM ._. in_IN the_DT absence_NN of_IN
          screening_NN )_) conditional_JJ on_IN no_DT death_NN from_IN competing_VBG risk_NN ._.
          Previous_JJ approaches_NNS [_NN 1_CD 2_CD 3_CD ]_NN used_VBD data_NNS from_IN refusers_NNS ,_,
          substituting_VBG 
          m_NN 
          
            R_NN 
           for_IN 
          m_NN 
          
            A_DT 
           ._. However_RB this_DT requires_VBZ a_DT strong_JJ unreasonable_JJ
          assumption_NN as_RB well_RB as_IN data_NNS from_IN refusers_NNS ,_, which_WDT is_VBZ often_RB
          not_RB available_JJ ._.
          As_IN an_DT alternative_NN ,_, we_PRP estimate_VBP an_DT upper_JJ bound_VBN on_IN the_DT
          reduction_NN in_IN the_DT population_NN cancer_NN mortality_NN rate_NN from_IN
          screening_NN by_IN estimating_VBG the_DT cancer_NN fatality_NN rate_NN in_IN the_DT
          absence_NN of_IN screening_NN using_VBG data_NNS from_IN interval_NN cancers_NNS ,_,
          namely_RB ,_, substituting_VBG 
          m_NN 
          
            I_PRP 
           =_SYM 
          m_NN 
          
            A_DT 
           ._. The_DT reason_NN this_DT is_VBZ an_DT upper_JJ bound_VBN is_VBZ that_IN cancers_NNS
          arising_VBG in_IN the_DT absence_NN of_IN screening_NN are_VBP composed_VBN of_IN
          cancers_NNS that_WDT would_MD have_VB arisen_VBN in_IN the_DT interval_NN after_IN a_DT
          negative_JJ screening_NN (_( had_VBD there_EX been_VBN screening_VBG )_) and_CC cancers_NNS
          that_WDT would_MD have_VB been_VBN detected_VBN on_IN a_DT previous_JJ screening_NN
          (_( had_VBD there_EX been_VBN screening_VBG )_) ._. The_DT latter_JJ cases_NNS are_VBP
          presumably_RB slower_JJR growing_VBG (_( a_DT type_NN of_IN length-biased_JJ
          sampling_VBG )_) with_IN better_JJR survival_NN ,_, so_RB using_VBG only_RB the_DT
          interval_NN cancers_NNS artificially_RB increases_VBZ the_DT estimated_VBN
          cancer-fatality_JJ rate_NN in_IN the_DT absence_NN of_IN screening_NN ._. (_( One_CD
          caveat_NN is_VBZ that_IN the_DT survival_NN of_IN interval_NN cancers_NNS may_MD be_VB
          improved_VBN due_JJ to_TO increased_VBN awareness_NN of_IN treatment_NN options_NNS
          that_WDT would_MD occur_VB as_IN part_NN of_IN a_DT screening_NN program_NN ._. If_IN the_DT
          effect_NN of_IN length_NN bias_NN is_VBZ relatively_RB small_JJ ,_, substituting_VBG 
          m_NN 
          
            I_PRP 
           for_IN 
          m_NN 
          
            A_DT 
           might_MD not_RB be_VB an_DT upper_JJ bound_VBN ,_, although_IN we_PRP believe_VBP it_PRP
          would_MD be_VB a_DT reasonable_JJ approximation_NN ._. )_)
        
        
          Step_NN 3_CD ._. Reduction_NNP in_IN population_NN cancer_NN mortality_NN
          rates_NNS due_JJ to_TO periodic_JJ screening_NN
          PSE_NNP estimates_VBZ the_DT reduction_NN in_IN population_NN cancer_NN
          mortality_NN rates_NNS due_JJ to_TO starting_VBG periodic_JJ cancer_NN screening_NN
          at_IN age_NN 
          a_DT instead_RB of_IN age_NN 
          b_SYM ,_, where_WRB ages_NNS 
          a_DT and_NN 
          b_SYM lie_VB in_IN the_DT range_NN of_IN ages_NNS at_IN
          initial_JJ screening_NN ._. (_( This_DT estimate_NN accounts_NNS for_IN competing_VBG
          risks_NNS through_IN the_DT use_NN of_IN 
          Surv_NNP (_( 
          a_DT ,_, 
          a_DT +_NN 3_LS )_) )_) ._. To_TO avoid_VB different_JJ rates_NNS
          of_IN overdiagnosis_NNS between_IN comparison_NN groups_NNS ,_, PSE_NNP compares_VBZ
          population_NN cancer_NN mortality_NN rates_NNS in_IN two_CD hypothetical_JJ
          scenarios_NNS involving_VBG full_JJ compliance_NN :_: Scenario_NN ,_, periodic_JJ
          screening_NN from_IN age_NN 
          a_DT until_IN age_NN 
          b_SYM and_CC Scenario_NN ,_, no_DT periodic_JJ
          screening_NN from_IN age_NN 
          a_DT to_TO age_NN 
          b_SYM -_: 1_CD followed_VBN by_IN screening_VBG at_IN age_NN 
          b_SYM ._. Scenario_NN involves_VBZ either_CC
          detection_NN on_IN the_DT first_JJ screen_NN at_IN age_NN 
          a_DT or_CC detection_NN in_IN the_DT interval_NN or_CC
          on_IN subsequent_JJ screens_NNS to_TO age_NN 
          b_SYM ._. Scenario_NN involves_VBZ either_CC
          detection_NN in_IN the_DT absence_NN of_IN screening_NN from_IN ages_NNS 
          a_DT to_TO 
          b_SYM -_: 1_CD or_CC detection_NN on_IN a_DT first_JJ
          screen_NN at_IN age_NN 
          b_SYM ._. Screening_NNP at_IN age_NN 
          b_SYM in_IN both_DT Scenarios_NNS and_CC avoids_VBZ
          differential_NN overdiagnosis_NNS rates_NNS because_IN ,_, if_IN 
          Assumption_NNP 1_CD holds_VBZ ,_, both_DT scenarios_NNS
          and_CC specify_VB equal_JJ probabilities_NNS of_IN detecting_VBG cancer_NN by_IN
          age_NN 
          b_SYM ._.
          More_RBR formally_RB we_PRP can_MD write_VB the_DT reduction_NN in_IN population_NN
          cancer_NN mortality_NN rates_NNS associated_VBN with_IN starting_VBG periodic_JJ
          cancer_NN screening_NN at_IN age_NN 
          a_DT instead_RB of_IN age_NN 
          b_SYM as_IN
          
          g_SYM =_SYM 
          pr_NN (_( cancer_NN mortality_NN under_IN Scenario_NN
          )_)
          -_: 
          pr_NN (_( cancer_NN mortality_NN under_IN Scenario_NN
          )_) ,_, (_( 4_LS )_)
          where_WRB
          
          pr_NN (_( cancer_NN mortality_NN under_IN Scenario_NN
          )_)
          =_SYM 
          pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN 
          A_DT detection_NN at_IN age_NN 
          i_NNP )_)
          +_NN 
          q_NN 
          
            F_NN 
           (_( 
          b_SYM )_) pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN
          
          F_NN detection_NN at_IN age_NN 
          b_SYM )_)
          
          pr_NN (_( cancer_NN mortality_NN under_IN Scenario_NN
          )_)
          =_SYM 
          q_NN 
          
            F_NN 
           (_( 
          a_DT )_) pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN
          
          F_NN detection_NN at_IN age_NN 
          a_DT )_)
          
          pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN 
          I_PRP detection_NN at_IN age_NN 
          i_NNP )_)
          
          pr_NN (_( cancer_NN death_NN in_IN cases_NNS |_NN type_NN 
          S_NNP detection_NN at_IN age_NN 
          i_NNP )_)
          and_CC cancer_NN death_NN in_IN cases_NNS refers_VBZ to_TO death_NN from_IN cancer_NN
          in_IN cases_NNS within_IN five_CD years_NNS of_IN cancer_NN detection_NN ._.
          Accounting_NNP for_IN deaths_NNS from_IN competing_VBG risks_NNS ,_, the_DT estimated_VBN
          probability_NN of_IN type_NN 
          d_SYM detection_NN at_IN age_NN 
          i_NNP ,_, conditional_JJ on_IN being_VBG alive_JJ at_IN
          age_NN 
          a_DT ,_, is_VBZ
          
          p_NN (_( type_NN 
          d_SYM detection_NN at_IN age_NN 
          i_NNP )_) =_SYM 
          Surv_NNP (_( 
          a_DT ,_, i_NNP )_) 
          q_NN 
          
            d_SYM 
           (_( 
          i_NNP )_) (_( 5_LS )_)
          Substituting_VBG (_( 5_LS )_) and_CC (_( 3_LS )_) into_IN (_( 4_LS )_) gives_VBZ
          
          To_TO simplify_VB (_( 6_CD )_) ,_, we_PRP define_VB
          
          Substituting_VBG (_( 7_CD )_) into_IN (_( 4_LS )_) gives_VBZ the_DT following_VBG simple_JJ
          estimate_NN ,_,
          
          
            basic_JJ 
           =_SYM (_( 
          Q_NNP 
          
            A_DT 
           
          m_NN 
          
            A_DT 
           +_NN 
          q_NN 
          
          F_NN 1_CD (_( 
          basic_JJ )_) 
          m_NN 
          
            F_NN 
           )_) -_: (_( 
          q_NN 
          
          F_NN 0_CD (_( 
          basic_JJ )_) 
          m_NN 
          
            F_NN 
           +_NN 
          Q_NNP 
          
            I_PRP 
           
          m_NN 
          
            I_PRP 
           +_NN 
          Q_NNP 
          
            S_NNP 
           
          m_NN 
          
            S_NNP 
           ._. (_( 8_CD )_)
          To_TO increase_VB the_DT stability_NN of_IN 
          
            basic_JJ 
           ,_, we_PRP used_VBD averages_NNS over_IN 
          k_NN =_SYM 3_CD intervals_NNS ,_, for_IN the_DT
          probabilities_NNS of_IN detection_NN on_IN the_DT first_JJ screenings_NNS at_IN age_NN
          
          a_DT and_NN at_IN age_NN 
          b_SYM ,_,
          
          Substituting_VBG (_( 9_CD )_) into_IN (_( 8_CD )_) gives_VBZ the_DT modified_VBN
          estimate_NN
          
          
            modified_VBN 
           =_SYM (_( 
          Q_NNP 
          
            A_DT 
           
          m_NN 
          
            A_DT 
           +_NN 
          q_NN 
          
          F_NN 1_CD 
          m_NN 
          
            F_NN 
           )_) -_: (_( 
          q_NN 
          
          F_NN 0_CD 
          m_NN 
          
            F_NN 
           +_NN 
          Q_NNP 
          
            I_PRP 
           
          m_NN 
          
            I_PRP 
           +_NN 
          Q_NNP 
          
            S_NNP 
           
          m_NN 
          
            S_NNP 
           )_) ._. (_( 10_CD )_)
          Invoking_NNP (_( 1_LS )_) ,_, we_PRP substitute_NN 
          q_NN 
          
          F_NN 0_CD +_NN 
          Q_NNP 
          
            I_PRP 
           +_NN 
          Q_NNP 
          
            S_NNP 
           -_: 
          Q_NNP 
          
          F_NN 1_CD for_IN 
          Q_NNP 
          
            A_DT 
           (_( 10_CD )_) ._. As_IN discussed_VBN previously_RB to_TO obtain_VB an_DT upper_JJ
          bound_VBN ,_, we_PRP also_RB set_VBD 
          m_NN 
          
            A_DT 
           =_SYM 
          m_NN 
          
            I_PRP 
           ._. This_DT gives_VBZ the_DT following_VBG estimated_VBN upper_JJ bound_VBN in_IN
          the_DT reduction_NN in_IN population_NN cancer_NN mortality_NN from_IN
          periodic_JJ screening_NN and_CC its_PRP$ asymptotic_JJ variance_NN
          
          
            upp_NN 
           =_SYM (_( 
          q_NN 
          
          F_NN 0_CD -_: 
          q_NN 
          
          F_NN 1_LS )_) (_( 
          m_NN 
          
            I_PRP 
           -_: 
          m_NN 
          
            F_NN 
           )_) +_NN 
          Q_NNP 
          
            S_NNP 
           (_( 
          m_NN 
          
            I_PRP 
           -_: 
          m_NN 
          
            S_NNP 
           )_) ,_, (_( 11_CD )_)
          
          
        
        
          Upper_NNP bound_VBN if_IN Assumption_NNP 1_CD is_VBZ violated_VBN
          There_EX are_VBP two_CD basic_JJ scenarios_NNS in_IN which_WDT 
          Assumption_NNP 1_CD could_MD be_VB violated_VBN ._.
          First_LS the_DT cancer_NN ,_, or_CC at_IN least_JJS the_DT detectable_JJ part_NN of_IN
          cancer_NN ,_, could_MD regress_NNS over_IN time_NN ._. This_DT would_MD most_RBS likely_JJ
          occur_VB if_IN the_DT cancer_NN were_VBD at_IN a_DT very_RB early_JJ stage_NN ._. Of_IN
          course_NN ,_, early_JJ lesions_NNS are_VBP the_DT principal_JJ targets_NNS of_IN
          screening_NN tests_NNS ._. Second_JJ ,_, chance_NN fluctuations_NNS in_IN the_DT
          results_NNS of_IN the_DT screening_NN test_NN might_MD mask_NN cancer_NN
          detection_NN ,_, particularly_RB if_IN the_DT interval_NN between_IN the_DT
          screening_NN tests_NNS were_VBD small_JJ ._. For_IN example_NN if_IN the_DT screening_NN
          test_NN were_VBD based_VBN on_IN a_DT sampling_VBG of_IN cells_NNS ,_, the_DT screening_NN
          test_NN may_MD ,_, by_IN chance_NN ,_, not_RB include_VB any_DT of_IN the_DT tumor_NN cells_NNS ._.
          For_IN many_JJ screening_NN modalities_NNS 
          Assumption_NNP 1_CD may_MD not_RB hold_VB ._.
          As_IN shown_VBN in_IN Figure_NN 1_CD ,_, if_IN 
          Assumption_NNP 1_CD did_VBD not_RB hold_VB ,_, PSE_NNP
          would_MD estimate_VB the_DT cancer_NN incidence_NN rate_NN in_IN the_DT absence_NN
          of_IN screening_NN as_IN 
          q_NN 
          
            A_DT 
           (_( 
          a_DT )_) +_NN δ_NN ,_, for_IN δ_NN >_NN 0_CD ,_, instead_RB of_IN 
          q_NN 
          
            A_DT 
           (_( 
          a_DT )_) ._. Thus_RB if_IN 
          Assumption_NNP 1_CD were_VBD not_RB satisfied_VBN ,_,
          PSE_NNP would_MD overestimate_NN the_DT cancer_NN incidence_NN rate_NN in_IN the_DT
          absence_NN of_IN screening_NN which_WDT 
          overestimates_NNS the_DT reduction_NN in_IN the_DT
          population_NN cancer_NN mortality_NN rate_NN ._. On_IN the_DT other_JJ hand_NN ,_, a_DT
          violation_NN of_IN 
          Assumption_NNP 1_CD would_MD also_RB imply_VB that_IN
          some_DT cancers_NNS detected_VBD on_IN screening_NN in_IN would_MD not_RB have_VB been_VBN
          detected_VBN on_IN the_DT last_JJ screening_NN in_IN which_WDT would_MD lower_VB the_DT
          reduction_NN in_IN the_DT population_NN cancer_NN mortality_NN rate_NN in_IN (_( 4_LS )_) ._.
          However_RB we_PRP think_VBP this_DT latter_JJ situation_NN would_MD have_VB a_DT small_JJ
          impact_NN relative_JJ to_TO the_DT former_JJ which_WDT involves_VBZ the_DT entire_JJ
          span_NN of_IN ages_NNS at_IN screening_NN and_CC not_RB just_RB the_DT last_JJ age_NN at_IN
          screening_NN ._.
          Thus_RB (_( 11_CD )_) is_VBZ an_DT upper_JJ bound_VBN for_IN two_CD reasons_NNS ._. First_LS it_PRP
          uses_VBZ interval_NN cancers_NNS to_TO estimate_VB fatality_NN rates_NNS
          following_VBG cancer_NN diagnosis_NN in_IN the_DT absence_NN of_IN screening_NN ._.
          Second_JJ it_PRP is_VBZ an_DT upper_JJ bound_VBN if_IN 
          Assumption_NNP 1_CD is_VBZ violated_VBN ._.
        
      
      
        Validation_NNP methodology_NN
        
          Minnesota_NNP Colon_NNP Cancer_NNP Control_NNP Study_NNP (_( MCCCS_NNP )_)
          Between_IN 1975_CD and_CC 1978_CD investigators_NNS randomized_JJ
          approximately_RB 45_CD ,_, 000_CD subjects_NNS to_TO either_CC 5_CD annual_JJ fecal_JJ
          occult_NN blood_NN screenings_NNS ,_, 3_CD biennial_JJ screenings_NNS ,_, or_CC no_DT
          screening_NN [_NN 6_CD 7_CD ]_NN ._. Due_JJ to_TO a_DT lower_JJR than_IN expected_VBN death_NN
          rate_NN among_IN controls_NNS ,_, the_DT investigators_NNS resumed_VBD screening_VBG
          between_IN 1982_CD and_CC 1986_CD ._. After_IN a_DT hiatus_NN of_IN screening_NN of_IN
          between_IN 3_CD and_CC 5_CD years_NNS ,_, the_DT annual_JJ screened_VBD group_NN received_VBD
          5_CD additional_JJ annual_JJ screenings_NNS and_CC the_DT biennial_JJ screened_VBD
          group_NN received_VBD 3_CD additional_JJ biennial_JJ screenings_NNS ._.
          Approximately_RB 14_CD percent_NN of_IN subjects_NNS randomized_JJ to_TO
          screening_NN did_VBD not_RB receive_VB screening_NN ._. Each_DT screening_NN cycle_NN
          consisted_VBD of_IN six_CD Hemocult_NNP slides_NNS with_IN planned_VBN definitive_JJ
          work-up_JJ if_IN any_DT slide_NN showed_VBD evidence_NN of_IN occult_NN blood_NN ._.
          Screenings_NNP for_IN the_DT annual_JJ groups_NNS were_VBD labeled_VBN as_IN on_IN time_NN
          if_IN they_PRP were_VBD done_VBN in_IN the_DT 9_CD to_TO 15_CD month_NN time_NN window_NN since_IN
          the_DT previous_JJ screening_NN ._. Screenings_NNP for_IN the_DT biennial_JJ group_NN
          were_VBD labeled_VBN as_IN on-time_JJ if_IN they_PRP were_VBD done_VBN 20_CD to_TO 28_CD months_NNS
          since_IN the_DT previous_JJ screening_NN ._. (_( The_DT longer_JJR time_NN window_NN was_VBD
          used_VBN to_TO keep_VB the_DT loss_NN of_IN data_NNS arbitrarily_RB to_TO no_DT more_JJR than_IN
          15_CD %_NN )_) Excluding_VBG the_DT first_JJ screening_NN after_IN the_DT resumption_NN
          of_IN screening_NN ,_, approximately_RB 93_CD percent_NN of_IN the_DT annual_JJ
          subsequent_JJ screenings_NNS and_CC 85_CD percent_NN of_IN the_DT biennial_JJ
          subsequent_JJ screenings_NNS were_VBD on-time_JJ ._. The_DT age_NN range_NN for_IN the_DT
          analysis_NN was_VBD 50_CD to_TO 75_CD ._. For_IN estimating_VBG the_DT age-specific_JJ
          incidence_NN of_IN cancer_NN among_IN controls_NNS ,_, we_PRP used_VBD data_NNS
          collected_VBN up_RP to_TO the_DT time_NN of_IN the_DT last_JJ screen_NN ,_, which_WDT was_VBD 16_CD
          years_NNS after_IN the_DT start_NN of_IN the_DT study_NN ._. We_PRP increased_VBD the_DT
          precision_NN of_IN the_DT estimated_VBN age-specific_JJ cancer_NN incidence_NN
          on_IN the_DT first_JJ screen_NN by_IN pooling_VBG data_NNS on_IN the_DT first_JJ
          screening_NN in_IN the_DT annual_JJ and_CC biennial_JJ arms_NNS ._. For_IN annual_JJ
          cancer_NN screening_NN ,_, age_NN was_VBD divided_VBN into_IN intervals_NNS of_IN 1_CD
          year_NN ._. For_IN biennial_JJ screening_NN ,_, age_NN was_VBD divided_VBN into_IN
          intervals_NNS of_IN 2_CD years_NNS ._.
        
        
          Health_NNP Insurance_NNP Plan_NNP of_IN Greater_NNP New_NNP York_NNP (_( HIP_NNP )_)
          Study_NN
          Starting_VBG in_IN 1963_CD ,_, approximately_RB 60_CD ,_, 000_CD women_NNS were_VBD
          randomly_RB assigned_VBN to_TO either_CC a_DT study_NN group_NN invited_VBN for_IN
          four_CD annual_JJ mammograms_NNS and_CC physical_JJ examinations_NNS or_CC to_TO a_DT
          control_NN group_NN that_WDT received_VBD no_DT screening_NN within_IN the_DT study_NN
          [_NN 8_CD ]_NN ._. Approximately_RB 1_CD /_NN 3_CD of_IN the_DT subjects_NNS in_IN the_DT study_NN
          group_NN refused_VBD the_DT first_JJ screening_NN and_CC received_VBD no_DT
          screenings_NNS ._. Screenings_NNP were_VBD labeled_VBN on-time_JJ if_IN they_PRP were_VBD
          done_VBN 9_CD to_TO 15_CD months_NNS after_IN a_DT previous_JJ screening_NN ._.
          Approximately_RB 79_CD percent_NN of_IN second_JJ screenings_NNS ,_, 76_CD percent_NN
          of_IN third_JJ screenings_NNS ,_, and_CC 73_CD percent_NN of_IN fourth_JJ screenings_NNS
          were_VBD on_IN time_NN ._. The_DT age_NN range_NN for_IN the_DT analysis_NN was_VBD 40_CD to_TO
          64_CD ._. For_IN estimating_VBG the_DT age-specific_JJ incidence_NN of_IN cancer_NN
          among_IN controls_NNS ,_, we_PRP used_VBD data_NNS collected_VBN up_RP to_TO the_DT time_NN of_IN
          the_DT last_JJ screen_NN ,_, which_WDT was_VBD 4_CD years_NNS after_IN the_DT start_NN of_IN the_DT
          study_NN ._.
        
        
          Mayo_NNP Lung_NNP Project_NNP (_( MLP_NNP )_)
          Between_IN 1971_CD and_CC 1976_CD approximately_RB 9_CD ,_, 200_CD male_JJ heavy_JJ
          smokers_NNS who_WP tested_VBD negative_JJ on_IN a_DT prevalence_NN (_( initial_JJ )_)
          screening_NN were_VBD randomized_JJ to_TO either_CC a_DT study_NN group_NN urged_VBD
          to_TO undergo_VB radiologic_JJ and_CC cytological_JJ screening_NN
          examinations_NNS every_DT 4_CD months_NNS for_IN 6_CD years_NNS or_CC a_DT control_NN
          group_NN that_IN at_IN study_NN entry_NN received_VBD a_DT recommendation_NN for_IN
          annual_JJ chest_NN X-_NNP rays_NNS with_IN no_DT further_JJ reminders_NNS [_NN 9_CD 10_CD ]_NN ._.
          Approximately_RB 7_CD percent_NN of_IN the_DT study_NN group_NN subjects_VBZ did_VBD
          not_RB receive_VB any_DT screenings_NNS ._.
          Because_IN PSE_NNP requires_VBZ a_DT single_JJ screening_NN time_NN at_IN each_DT
          round_NN of_IN screening_NN ,_, we_PRP restricted_VBD PSE_NNP to_TO the_DT screenings_NNS
          in_IN which_WDT the_DT time_NN between_IN cytology_NN and_CC x-ray_JJ was_VBD less_JJR
          than_IN 3_CD weeks_NNS ._. Screenings_NNP were_VBD labeled_VBN as_IN on-time_JJ if_IN they_PRP
          were_VBD done_VBN within_IN 3_CD ._. 5_CD to_TO 5_CD ._. 5_CD months_NNS of_IN the_DT previous_JJ
          screening_NN and_CC the_DT time_NN between_IN cytology_NN and_CC x-ray_JJ was_VBD
          less_JJR than_IN 3_CD weeks_NNS ._. Approximately_RB 85_CD percent_NN of_IN the_DT
          subsequent_JJ screenings_NNS were_VBD on-time_JJ ._.
          Only_RB yearly_JJ age_NN data_NNS were_VBD available_JJ ._. Because_IN the_DT
          screenings_NNS in_IN the_DT Mayo_NNP Lung_NNP Project_NNP were_VBD scheduled_VBN at_IN 4_CD
          month_NN intervals_NNS ,_, yearly_JJ cancer_NN incidence_NN data_NNS for_IN types_NNS 
          I_PRP and_CC 
          S_NNP detection_NN are_VBP approximated_JJ using_VBG
          the_DT sums_NNS of_IN counts_NNS for_IN three_CD successive_JJ screens_NNS ._. Because_IN
          all_DT subjects_NNS in_IN the_DT control_NN group_NN had_VBD an_DT initial_JJ
          screening_NN ,_, we_PRP pooled_VBN data_NNS for_IN detection_NN rates_NNS on_IN initial_JJ
          screenings_NNS in_IN the_DT study_NN and_CC control_NN groups_NNS ._.
          Unfortunately_RB the_DT initial_JJ screening_NN in_IN the_DT control_NN
          group_NN greatly_RB complicated_VBD the_DT validation_NN ,_, which_WDT requires_VBZ
          that_IN no_DT screening_NN be_VB performed_VBN in_IN the_DT control_NN group_NN ._. In_IN
          order_NN to_TO better_RBR approximate_JJ a_DT control_NN group_NN that_WDT received_VBD
          no_DT screening_NN ,_, we_PRP only_RB used_VBD data_NNS in_IN controls_NNS starting_VBG 6_CD
          years_NNS after_IN randomization_NN ._. The_DT underlying_VBG assumption_NN is_VBZ
          that_IN by_IN 6_CD years_NNS ,_, most_JJS cancers_NNS detected_VBD on_IN the_DT prevalence_NN
          screening_NN would_MD have_VB progressed_VBN to_TO clinical_JJ cancer_NN in_IN the_DT
          absence_NN of_IN intervention_NN ._. (_( This_DT may_MD not_RB be_VB true_JJ because_IN of_IN
          the_DT likely_JJ possibility_NN of_IN overdiagnosis_NNS [_NN 10_CD ]_NN and_CC lead_VB
          times_NNS that_WDT may_MD exceed_VB 6_CD years_NNS ,_, but_CC it_PRP may_MD serve_VB as_IN a_DT
          useful_JJ approximation_NN if_IN the_DT amount_NN of_IN overdiagnosis_NNS is_VBZ
          small_JJ )_) ._. Due_JJ to_TO the_DT 6_CD -_: year_NN wash-out_JJ period_NN ,_, we_PRP start_VBP the_DT
          age_NN range_NN for_IN PSE_NNP at_IN 51_CD instead_RB of_IN 45_CD ._. We_PRP chose_VBD 6_CD years_NNS
          for_IN the_DT washout_NN period_NN as_IN a_DT compromise_NN ._. We_PRP thought_VBD a_DT
          longer_JJR washout_NN period_NN would_MD have_VB greatly_RB restricted_VBN the_DT
          age_NN range_NN under_IN study_NN and_CC a_DT shorter_JJR washout_NN period_NN would_MD
          have_VB had_VBD a_DT much_RB more_RBR limited_JJ effect_NN ._.
          We_PRP illustrate_VBP the_DT calculations_NNS for_IN the_DT analysis_NN of_IN the_DT
          HIP_NNP data_NN on_IN breast_NN cancer_NN screening_NN ._. The_DT probability_NN of_IN a_DT
          women_NNS surviving_VBG competing_VBG risk_NN from_IN age_NN 40_CD to_TO each_DT
          successive_JJ age_NN up_IN to_TO age_NN 64_CD is_VBZ 1_CD ._. ,_, 1_CD ._. ,_, 0_CD ._. 99_CD ,_, 0_CD ._. 99_CD ,_, 0_CD ._. 99_CD ,_,
          0_CD ._. 99_CD ,_, 0_CD ._. 99_CD ,_, 0_CD ._. 98_CD ,_, 0_CD ._. 98_CD ,_, 0_CD ._. 98_CD ,_, 0_CD ._. 97_CD ,_, 0_CD ._. 97_CD ,_, 0_CD ._. 96_CD ,_, 0_CD ._. 96_CD ,_, 0_CD ._. 95_CD ,_,
          0_CD ._. 95_CD ,_, 0_CD ._. 94_CD ,_, 0_CD ._. 93_CD ,_, 0_CD ._. 92_CD ,_, 0_CD ._. 92_CD ,_, 0_CD ._. 91_CD ,_, 0_CD ._. 9_CD ,_, 0_CD ._. 89_CD ,_, 0_CD ._. 87_CD ._. Using_VBG
          these_DT probabilities_NNS and_CC data_NNS from_IN Tables_NNP 1_CD and_CC 5_CD ,_, we_PRP
          computed_JJ 
          q_NN 
          
            F_NN 
           =_SYM ._. 00166_CD ,_, 
          q_NN 
          
            Fs_NNP 
           =_SYM ._. 00373_CD ,_, 
          Q_NNP 
          
            I_PRP 
           =_SYM ._. 0151_CD ,_, 
          Q_NNP 
          
            S_NNP 
           =_SYM ._. 0338_CD ,_, 
          m_NN 
          
            I_PRP 
           =_SYM ._. 334_CD ,_, and_CC 
          m_NN 
          
            S_NNP 
           =_SYM ._. 123_CD ,_, Substituting_VBG into_IN (_( 11_CD )_) gave_VBD 
          
            upp_NN 
           =_SYM ._. 00676_CD ._. To_TO estimate_VB the_DT variance_NN we_PRP computed_JJ 
          v_NN 
          
            I_PRP 
           =_SYM ._. 00497_CD ,_, 
          v_NN 
          
            S_NNP 
           =_SYM ._. 00189_CD ,_, 
          V_NNP 
          
          F_NN 0_CD =_SYM ._. 00000056_CD ,_, 
          V_NNP 
          
          F_NN 1_CD =_SYM ._. 0000023_CD ._. Substituting_VBG
          into_IN (_( 12_CD )_) gave_VBD 
          var_NN (_( 
          
            upp_NN 
           )_) =_SYM ._. 0000090_CD ._.
        
      
      
        Results_NNS
        
          Minnesota_NNP Colon_NNP Cancer_NNP Control_NNP Study_NNP (_( MCCCS_NNP )_)
          There_EX is_VBZ a_DT large_JJ overlap_VB in_IN the_DT confidence_NN intervals_NNS
          for_IN the_DT PSE_NNP estimated_VBD upper_JJ bound_VBN from_IN screened_VBD subjects_NNS
          and_CC PSE_NNP estimates_NNS from_IN all_DT subjects_NNS (_( Figure_NN 2_LS )_) ._. Also_RB ,_, the_DT
          95_CD %_NN confidence_NN interval_NN for_IN the_DT estimated_VBN difference_NN
          includes_VBZ zero_CD (_( Figure_NN 3_LS )_) ,_, indicating_VBG that_IN the_DT upper_JJ bound_VBN
          estimate_NN is_VBZ reasonable_JJ ._. The_DT estimated_VBN mortality_NN reduction_NN
          in_IN the_DT screening_NN program_NN is_VBZ similar_JJ to_TO the_DT PSE_NNP estimates_NNS
          (_( Figure_NN 2_LS )_) because_IN the_DT long-duration_JJ of_IN screening_NN (_( 5_CD
          annual_JJ or_CC 3_CD biennial_JJ screenings_NNS followed_VBN by_IN 3_CD -_: 5_CD years_NNS
          hiatus_NN followed_VBN by_IN 5_CD annual_JJ or_CC 3_CD biennial_JJ screenings_NNS )_) in_IN
          the_DT trial_NN approximated_JJ the_DT 21_CD years_NNS of_IN periodic_JJ
          screening_NN ._.
        
        
          Health_NNP Insurance_NNP Plan_NNP of_IN Greater_NNP New_NNP York_NNP (_( HIP_NNP )_)
          Study_NN
          As_IN in_IN the_DT previous_JJ example_NN ,_, there_EX is_VBZ a_DT large_JJ overlap_VB
          in_IN the_DT confidence_NN intervals_NNS for_IN the_DT PSE_NNP estimated_VBD upper_JJ
          bound_VBN from_IN screened_VBD subjects_NNS and_CC PSE_NNP estimates_NNS from_IN all_DT
          subjects_NNS (_( Figure_NN 2_LS )_) ._. Also_RB ,_, similar_JJ to_TO the_DT previous_JJ
          example_NN ,_, the_DT 95_CD %_NN confidence_NN interval_NN for_IN the_DT difference_NN
          included_VBD zero_CD (_( Figure_NN 3_LS )_) indicating_VBG that_IN the_DT upper_JJ bound_VBN
          estimate_NN is_VBZ reasonable_JJ ._. The_DT PSE_NNP estimates_NNS were_VBD higher_JJR
          than_IN the_DT estimated_VBN effect_NN of_IN the_DT screening_NN program_NN in_IN the_DT
          trial_NN because_IN the_DT former_NN was_VBD based_VBN on_IN 24_CD annual_JJ
          screenings_NNS and_CC the_DT latter_NN was_VBD based_VBN on_IN only_RB 4_CD annual_JJ
          screenings_NNS ._.
        
        
          Mayo_NNP Lung_NNP Project_NNP (_( MLP_NNP )_)
          Unlike_IN the_DT other_JJ examples_NNS the_DT confidence_NN intervals_NNS for_IN
          PSE_NNP estimates_NNS from_IN screened_VBD subjects_NNS and_CC PSE_NNP estimates_NNS
          from_IN all_DT subjects_NNS differed_VBD considerably_RB (_( Figure_NN 2_LS )_) ._. We_PRP
          think_VBP 
          Assumption_NNP 1_CD may_MD not_RB have_VB held_VBN due_JJ
          to_TO the_DT short_JJ interval_NN between_IN screens_NNS and_CC to_TO the_DT fact_NN
          that_IN the_DT performance_NN of_IN sputum_NN cytology_NN screening_NN depends_VBZ
          on_IN sampling_VBG of_IN the_DT tumor_NN cells_NNS ._. Although_IN the_DT 95_CD %_NN
          confidence_NN interval_NN for_IN the_DT difference_NN included_VBD zero_CD
          (_( Figure_NN 3_LS )_) ,_, its_PRP$ large_JJ width_NN means_VBZ that_IN a_DT substantial_JJ bias_NN
          cannot_NN be_VB ruled_VBN out_RP ._. The_DT PSE_NNP estimates_NNS were_VBD higher_JJR than_IN
          the_DT estimated_VBN effect_NN of_IN the_DT screening_NN program_NN in_IN the_DT
          trial_NN because_IN (_( 
          i_NNP )_) the_DT former_NN is_VBZ based_VBN on_IN 24_CD years_NNS
          of_IN screening_NN while_IN the_DT latter_NN is_VBZ based_VBN on_IN only_RB 6_CD years_NNS
          and_CC (_( 
          ii_NN )_) the_DT effect_NN in_IN the_DT latter_NN was_VBD
          reduced_VBN by_IN a_DT prevalence_NN screening_NN in_IN the_DT controls_NNS ._. PSE_NNP
          for_IN screened_VBD subjects_NNS does_VBZ not_RB use_VB any_DT data_NNS from_IN the_DT
          control_NN group_NN ._. With_IN PSE_NNP for_IN all_DT subjects_NNS ,_, we_PRP assumed_VBD a_DT
          wash-out_JJ period_NN to_TO try_VB to_TO remove_VB the_DT effect_NN of_IN the_DT
          prevalence_NN screen_NN ._.
          The_DT results_NNS indicate_VBP that_IN a_DT PSE_NNP estimated_VBD upper_JJ bound_VBN
          based_VBN on_IN subjects_NNS screened_VBD is_VBZ not_RB unreasonable_JJ when_WRB
          compared_VBN to_TO the_DT PSE_NNP estimate_NN based_VBN on_IN all_DT subjects_NNS in_IN the_DT
          randomized_JJ trial_NN ._. Because_IN of_IN sampling_VBG variability_NN it_PRP is_VBZ
          not_RB surprising_VBG that_IN the_DT point_NN estimate_NN of_IN the_DT upper_JJ bound_VBN
          can_MD be_VB smaller_JJR than_IN the_DT point_NN estimate_NN based_VBN on_IN all_DT
          subjects_NNS ._.
          We_PRP caution_VBP that_IN violations_NNS of_IN 
          Assumption_NNP 2_CD could_MD have_VB a_DT
          substantial_JJ impact_NN ._. 
          Assumption_NNP 2_CD depends_VBZ on_IN the_DT
          cumulative_JJ effect_NN of_IN birth_NN cohort_NN from_IN ages_NNS 
          a_DT to_TO 
          b_SYM ._. According_VBG to_TO Moran_NNP [_NN 21_CD ]_NN the_DT
          relative_JJ bias_NN due_JJ to_TO violation_NN of_IN 
          Assumption_NNP 2_CD is_VBZ particularly_RB large_JJ
          if_IN the_DT age-specific_JJ incidence_NN on_IN the_DT first_JJ screen_NN changes_NNS
          little_JJ with_IN age_NN and_CC interval_NN and_CC subsequent_JJ cancers_NNS are_VBP
          relatively_RB rare_JJ ._. In_IN that_DT case_NN Moran_NNP advised_VBD that_IN other_JJ
          methods_NNS be_VB applied_VBN ._. One_CD way_NN to_TO reduce_VB bias_NN from_IN 
          Assumption_NNP 2_CD is_VBZ to_TO only_RB estimate_VB
          the_DT effect_NN of_IN screening_NN for_IN at_IN most_JJS 5_CD years_NNS ._. That_DT way_NN the_DT
          cumulative_JJ birth_NN cohort_NN effect_NN would_MD be_VB limited_VBN to_TO only_RB 5_CD
          years_NNS ._.
        
      
      
        Conclusion_NNP
        We_PRP think_VBP the_DT major_JJ role_NN of_IN PSE_NNP is_VBZ to_TO rule_VB out_IN screening_NN
        modalities_NNS that_WDT have_VBP little_JJ benefit_NN ._. This_DT information_NN is_VBZ
        useful_JJ when_WRB making_VBG policy_NN decisions_NNS about_IN screening_NN ,_, or_CC
        when_WRB considering_VBG a_DT large_JJ randomized_JJ trial_NN to_TO definitively_RB
        compare_VB benefits_NNS and_CC harms_NNS of_IN screening_NN strategies_NNS ._. Because_IN
        PSE_NNP is_VBZ estimating_VBG an_DT upper_JJ bound_VBN when_WRB 
        Assumption_NNP 1_CD is_VBZ violated_VBN ,_, if_IN PSE_NNP
        estimates_NNS little_JJ reduction_NN in_IN population_NN cancer_NN mortality_NN ,_,
        the_DT true_JJ reduction_NN in_IN population_NN cancer_NN mortality_NN due_JJ to_TO
        periodic_JJ screening_NN is_VBZ likely_JJ small_JJ ._. If_IN any_DT effects_NNS of_IN birth_NN
        cohort_NN are_VBP minimal_JJ ,_, further_JJ evaluation_NN with_IN a_DT randomized_JJ
        trial_NN would_MD not_RB be_VB warranted_VBN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        SGB_NNP wrote_VBD the_DT initial_JJ draft_NN ._. DE_NNP created_VBD Tables_NNP 1_CD 2_CD 3_CD 4_CD
        5_CD from_IN the_DT data_NNS files_NNS and_CC provided_VBN many_JJ helpful_JJ suggestions_NNS ._.
        BSK_NNP and_CC PCP_NNP substantially_RB improved_VBD the_DT manuscript_NN ._.
      
    
  
